Nature Medicine, Published online: 23 July 2026; doi:10.1038/s41591-026-04534-z
In a pair of pivotal phase 3, placebo-controlled, randomized clinical trials, the oral JAK1 inhibitor povorcitinib significantly reduced abscesses and inflammatory nodules in patients with moderate to severe hidradenitis suppurativa.